These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 23275385)

  • 1. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age.
    Maron BJ; Rowin EJ; Casey SA; Haas TS; Chan RH; Udelson JE; Garberich RF; Lesser JR; Appelbaum E; Manning WJ; Maron MS
    Circulation; 2013 Feb; 127(5):585-93. PubMed ID: 23275385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
    Maron BJ; Rowin EJ; Casey SA; Link MS; Lesser JR; Chan RH; Garberich RF; Udelson JE; Maron MS
    J Am Coll Cardiol; 2015 May; 65(18):1915-28. PubMed ID: 25953744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
    Maron BJ; Rowin EJ; Casey SA; Lesser JR; Garberich RF; McGriff DM; Maron MS
    Circulation; 2016 Jan; 133(1):62-73. PubMed ID: 26518766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertrophic cardiomyopathy with longevity to 90 years or older.
    Maron BJ; Casey SA; Haas TS; Kitner CL; Garberich RF; Lesser JR
    Am J Cardiol; 2012 May; 109(9):1341-7. PubMed ID: 22381158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children.
    Decker JA; Rossano JW; Smith EO; Cannon B; Clunie SK; Gates C; Jefferies JL; Kim JJ; Price JF; Dreyer WJ; Towbin JA; Denfield SW
    J Am Coll Cardiol; 2009 Jul; 54(3):250-4. PubMed ID: 19589438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertrophic cardiomyopathy: risk factors for life and living benefits insurance.
    Pokorski RJ
    J Insur Med; 2002; 34(1):43-60. PubMed ID: 15303593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the risk of sudden death in hypertrophic cardiomyopathy].
    Sadoul N; de Chillou C; Aliot E; McKenna WJ
    Arch Mal Coeur Vaiss; 1999 Apr; 92 Spec No 1():65-73. PubMed ID: 10326160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
    Ruiz-Salas A; García-Pinilla JM; Cabrera-Bueno F; Fernández-Pastor J; Peña-Hernández J; Medina-Palomo C; Barrera-Cordero A; De Teresa E; Alzueta J
    Europace; 2016 May; 18(5):773-7. PubMed ID: 25855675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
    Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand.
    Songsirisuk N; Kittipibul V; Methachittiphan N; Charoenattasil V; Zungsontiporn N; Spanuchart I; Buppajarntham S; Mankongpaisarnrung C; Satitthummanid S; Srimahachota S; Chattranukulchai P; Boonyaratavej Songmuang S; Puwanant S
    BMC Cardiovasc Disord; 2019 Jan; 19(1):1. PubMed ID: 30606129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syncope and risk of sudden death in hypertrophic cardiomyopathy.
    Spirito P; Autore C; Rapezzi C; Bernabò P; Badagliacca R; Maron MS; Bongioanni S; Coccolo F; Estes NA; Barillà CS; Biagini E; Quarta G; Conte MR; Bruzzi P; Maron BJ
    Circulation; 2009 Apr; 119(13):1703-10. PubMed ID: 19307481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of death and mortality in hypertrophic cardiomyopathy patients with implantable defibrillators in Sweden.
    Magnusson P; Gadler F; Liv P; Mörner S
    J Cardiovasc Med (Hagerstown); 2016 Jul; 17(7):478-84. PubMed ID: 26808417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy: report from the registry data in Japan.
    Goto D; Kinugawa S; Hamaguchi S; Sakakibara M; Tsuchihashi-Makaya M; Yokota T; Yamada S; Yokoshiki H; Tsutsui H;
    J Cardiol; 2013 Jan; 61(1):65-70. PubMed ID: 23078864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.